83% of patients taking TYSABRI had no sustained physical disability progression for 12 weeks vs 71% with placebo (primary endpoint: percentage with sustained increase in disability was 17% vs 29%; p<0.001)1,2
View the complete AFFIRM study description.
Download a guide designed to provide information that can help practice administrators and other key practice staff understand the administrative needs and various aspects of the reimbursement process: prescribing and ordering TYSABRI, billing and claims filing, patient support, healthcare reform, FAQs, and a Managed Care Glossary.
Download resources and sample forms that your office might find useful.
Download resources and sample forms that your office, hospital, and/or infusion site might find useful.
Only prescribers, pharmacies, and infusion sites enrolled in the TOUCH® Prescribing Program (REMS program) are able to prescribe, distribute, or infuse TYSABRI.
AFFIRM=NAtalizumab Safety and EFFIcacy in Relapsing-Remitting MS.